Starting with one bottle, Beetles Gel Polish invites the nail community to take part in a more sustainable approach to nail bottle recycling.
NEW YORK, June 4, 2026 /PRNewswire/ -- Beetles Gel Polish today announced the Beetles Loves Earth Free Recycling Program, a new initiative launched in partnership with international recycling leader TerraCycle® to help recycle dry, empty glass gel polish and nail polish bottles from any brand, along with their associated plastic caps. The program reflects Beetles Gel Polish's proactive commitment to reducing the environmental burden of nail empties and inviting the nail community to start with one bottle and take responsibility together.
Giving Nail Empties a New Life
Gel polish and nail polish bottles are not accepted in most curbside recycling programs due to residual product, complex cleaning needs and processing costs that can outweigh recovered material value. As a result, many nail lovers are left with empty or unused bottles at home and no clear way to recycle them.
Through the Beetles Loves Earth Free Recycling Program, all accepted items are recycled into raw materials and used to manufacture new products. Glass components are processed into recycled raw materials used in construction products including bricks, cement and concrete, giving nail empties a new life beyond the bottle.
How Beetles Loves Earth Works
Consumers and nail professionals can visit the official Beetles Gel Polish campaign page to review the recycling guidelines, then bring eligible dry, empty glass gel polish and nail polish bottles from any brand, along with their associated plastic caps, to a designated Beetles Loves Earth drop-off point.
To recognize and encourage participation, Beetles Gel Polish will offer tiered rewards based on the number of eligible bottles returned, including products, coupons and limited-edition gift boxes. The brand also plans to develop a mail-in recycling option to make participation more convenient for consumers in rural and remote areas.
A Call to the Nail Community
By accepting eligible empties from any brand, Beetles Gel Polish invites the wider nail community to join the effort, including at-home users, nail salon owners, nail artists, creators, community sustainability advocates, school clubs, local organizers, shop owners and fellow nail brands.
The Beetles Loves Earth Free Recycling Program is available through drop-off points across the U.S., with expansion into more states and cities planned so more nail lovers can participate wherever they are. Supporters interested in hosting a collection bin can complete the participation form and become a Beetles Loves Earth Recycling Ambassador, helping bring responsible nail bottle recycling to more local communities.
Responsible Beauty Beyond the Bottle
Beetles Gel Polish believes beauty should not end when the last coat dries. Built on a cruelty-free philosophy and ongoing efforts toward more responsible product and packaging practices, the Beetles Loves Earth Free Recycling Program extends the brand's responsibility to what happens after the bottle is empty. Through collaboration with TerraCycle® and the nail community, the brand is working to help reduce the waste impact associated with nail routines, starting with one empty nail bottle.
Start With the Bottles You Have
Consumers and community partners can learn more and join the Beetles Loves Earth Free Recycling Program by visiting the official Beetles Gel Polish website, turning a simple action into a meaningful step toward caring for the planet.
About Beetles Gel Polish
Beetles Gel Polish offers gel polish, nail color, tools and at-home manicure essentials for salon-inspired nails at home. The brand is cruelty-free and does not test on animals. Through Beetles Loves Earth, the brand is helping nail lovers take part in more responsible nail bottle recycling. Learn more at: https://www.beetlesgel.com/pages/blogs
About TerraCycle®
TerraCycle® is an international leader in innovative sustainability solutions, creating and operating first-of-their-kind platforms in recycling, recycled materials, and reuse. Across 18 countries, TerraCycle® is on a mission to eliminate the idea of waste and develop practical solutions for today's complex waste challenges. The company engages an expansive multi-stakeholder community, from Fortune 500 companies to schools and households, across a wide range of accessible programs and has raised millions for schools and nonprofits since its founding more than 20 years ago. To learn more about TerraCycle® and join them on their journey to move the world from a linear economy to a circular one, please visit www.terracycle.com.
Press Contact
Beetles Gel Polish PR Team
brand@beetlesgel.com
Sue Kauffman
TerraCycle
sue.kauffman@terracycle.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Beetles Gel Polish Partners With TerraCycle® to Launch "Beetles Loves Earth," Advancing Recycling for Nail Empties
|
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
